Intraperitoneal administration of recombinant human erythropoietin in uremic animals

J. M. Bargman, A. Breborowicz, H. Rodela, K. Sombolos, D. G. Oreopoulos

Research output: Contribution to journalArticle

8 Scopus citations

Abstract

Previous protocols of administration of recombinant human erythropoietin to patients with end-stage renal disease have been by the i.v. route. Because this method would be impractical for the continuous ambulatory peritoneal dialysis patient, we designed an i.p. dosing protocol in uremic rabbits to examine whether significant amounts of this hormone could be absorbed from the peritoneal cavity. Our results demonstrate that almost all of the erythropoietin is absorbed (or absorbed) during a prolonged dwell when administered undiluted by dialysate.

Original languageEnglish (US)
Pages (from-to)249-252
Number of pages4
JournalPeritoneal Dialysis International
Volume8
Issue number4
DOIs
StatePublished - Jan 1 1988

ASJC Scopus subject areas

  • Nephrology

Fingerprint Dive into the research topics of 'Intraperitoneal administration of recombinant human erythropoietin in uremic animals'. Together they form a unique fingerprint.

  • Cite this

    Bargman, J. M., Breborowicz, A., Rodela, H., Sombolos, K., & Oreopoulos, D. G. (1988). Intraperitoneal administration of recombinant human erythropoietin in uremic animals. Peritoneal Dialysis International, 8(4), 249-252. https://doi.org/10.1177/089686088800800404